Despite the quick evolution of drug innovation, it remains difficult to target certain genomic information with traditional small molecule and antibody drugs. Currently only 1.5% of the human genome is amenable to these types of therapies, while an estimated 80% or more are non-druggable proteins that cannot be targeted by current methods – a substantial hurdle in producing effective treatments for diseases related to recombinant proteins and antibodies. As such, nucleic acid medicines have become increasingly popular as potential solutions due to their ability to address previously unapproachable genetic components underlying disease states.
Nucleic acid drugs boast an impressively wide range of target selection, allowing for their increased potential for success and less vulnerability to drug resistance. Furthermore, these therapies are applicable in a variety of therapeutic areas – making them a promising choice for many conditions.
Nucleic acid drugs are revolutionizing the way we treat diseases, offering treatments that specifically target disease-causing genes or RNA fragments. This novel class of drug has already been used to great effect in genetic and viral illnesses, as well as cancer therapies – with promising results on even more serious conditions. Already, this third generation of medicine is quickly becoming a go-to for doctors worldwide due to its remarkable capacity to address complex medical issues where others may have failed.